Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
The New York Proton Center
Hoffmann-La Roche
Neonc Technologies, Inc.
University of Nebraska
National Cancer Institute (NCI)
University of Southern California
Massive Bio, Inc.
National Cancer Institute (NCI)
Taproot Health
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Children's Oncology Group
City of Hope Medical Center
Technische Universität Dresden
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Children's Oncology Group
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Vanderbilt University
M.D. Anderson Cancer Center
Yale University
University of California, San Francisco
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Duke University
Children's Oncology Group
Memorial Sloan Kettering Cancer Center